Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AEMDOTCMKTS:ARTHNASDAQ:NVIVOTCMKTS:RDGL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEMDAethlon Medical$1.51+2.0%$1.65$1.35▼$5.92$3.88M1.888,639 shs17,052 shsARTHArch Therapeutics$1.14-3.4%$1.95$0.39▼$18.00$5.40M3.535,995 shs316 shsNVIVInVivo Therapeutics$0.58$0.22▼$2.40$997K0.658.25 million shs1.89 million shsRDGLVivos$0.11$0.07$0.04▼$0.12$40.83M1.53720,377 shs230,748 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEMDAethlon Medical+5.73%+5.00%-11.58%-24.03%-71.37%ARTHArch Therapeutics-3.39%+2.01%-46.73%-70.08%-62.00%NVIVInVivo Therapeutics0.00%0.00%0.00%-52.32%-75.89%RDGLVivos-1.41%-0.47%+54.05%+58.37%-3.76%Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEMDAethlon Medical1.3101 of 5 stars3.53.00.00.01.10.00.6ARTHArch TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARDGLVivosN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEMDAethlon Medical3.00Buy$10.00561.42% UpsideARTHArch TherapeuticsN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/ARDGLVivosN/AN/AN/AN/ACurrent Analyst RatingsLatest NVIV, AEMD, RDGL, and ARTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/4/2024AEMDAethlon MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $10.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEMDAethlon Medical$574.25K6.90N/AN/A$6.56 per share0.23ARTHArch Therapeutics$80K67.55N/AN/A($2.43) per share-0.47NVIVInVivo TherapeuticsN/AN/AN/AN/A$6.48 per shareN/ARDGLVivos$20K2,041.57N/AN/A($0.02) per share-5.25Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEMDAethlon Medical-$12.03M-$4.99N/AN/AN/AN/A-106.28%-86.60%6/26/2024 (Estimated)ARTHArch Therapeutics-$6.98MN/A0.00∞N/A-6,809.45%N/A-386.74%5/20/2024 (Estimated)NVIVInVivo Therapeutics-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/ARDGLVivos-$2.89MN/A0.00∞N/A-9,524.89%N/A-180.12%5/2/2024 (Estimated)Latest NVIV, AEMD, RDGL, and ARTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023RDGLVivosN/A-$0.01-$0.01-$0.01N/AN/A2/20/2024Q1 2024ARTHArch TherapeuticsN/A-$0.57-$0.57-$0.57N/A$0.05 million2/14/2024Q3 2024AEMDAethlon Medical-$1.23-$1.37-$0.14-$1.37N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEMDAethlon MedicalN/AN/AN/AN/AN/AARTHArch TherapeuticsN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/ARDGLVivosN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEMDAethlon MedicalN/A3.933.93ARTHArch TherapeuticsN/A0.160.04NVIVInVivo TherapeuticsN/A14.3014.30RDGLVivosN/A6.576.57OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEMDAethlon Medical1.99%ARTHArch Therapeutics6.91%NVIVInVivo Therapeutics13.78%RDGLVivosN/AInsider OwnershipCompanyInsider OwnershipAEMDAethlon Medical4.00%ARTHArch Therapeutics4.50%NVIVInVivo Therapeutics2.45%RDGLVivos18.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAEMDAethlon Medical152.62 million2.52 millionOptionableARTHArch Therapeutics84.74 million4.53 millionNot OptionableNVIVInVivo Therapeutics63.11 million3.03 millionNot OptionableRDGLVivos1388.87 million316.93 millionNot OptionableNVIV, AEMD, RDGL, and ARTH HeadlinesSourceHeadlineVivos Inc RDGLmorningstar.com - April 15 at 12:36 AMVivos Therapeutics, Inc: Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursementfinanznachrichten.de - April 11 at 5:24 PMVivos Stock (OTC:RDGL), Quotes and News Summarybenzinga.com - March 23 at 12:35 AMVivos Incthestreet.com - February 23 at 7:06 AM3 Stocks to Turn $1,000 Into $1 Million: February 2024investorplace.com - February 22 at 12:39 PMSpeculation Tuesday: 2 Call Options and 1 Penny Stock to Considertheglobeandmail.com - January 31 at 1:26 AMVivos: Unregistered Sales Of Equity Securities, Other Events, Financial Statements And Exhibitscbonds.com - December 29 at 9:59 AMNew Hope In Cancer Battle: FDA Grants Breakthrough Device Status To Vivos Inc.'s RadioGelmsn.com - December 21 at 3:43 PMRadiogel Precision Radionuclide Therapy Receives FDA Breakthrough Device Designationfinance.yahoo.com - December 20 at 1:10 PMRadiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designationfinance.yahoo.com - December 20 at 1:10 PMVivos Inc. Announces Certification of Three New IsoPet® Precision Radionuclide Therapy Regional Clinicsfinance.yahoo.com - August 7 at 10:56 AMCupom de desconto Vivo R$119 Off → (4 Cupons Vivo) Junho 2023catracalivre.com.br - June 21 at 8:15 AMGloboNews ao vivog1.globo.com - May 25 at 10:26 PMVivos Inc. (RDGL) Stock Historical Prices & Data - Yahoo Financefinance.yahoo.com - May 15 at 10:53 PMCupom Vivo - Maio 2023tecmundo.com.br - May 11 at 10:08 PMIsaura ao vivo na Rádio Observadorobservador.pt - April 29 at 3:54 PMVivo V27 Pro in for reviewgsmarena.com - February 22 at 11:54 PMTrês jovens são retirados vivos dos escombros após 8 dias do terremoto na Turquiabemparana.com.br - February 16 at 2:58 PMVivos Inc Files a New Patent on Alternate Particles for Precision Radionuclide Therapyfinance.yahoo.com - January 11 at 9:39 AMRDGL.PK - Vivos Inc | Stock Price & Latest News | Reutersreuters.com - January 5 at 2:29 PMCupom de desconto Vivo Frete Grátisuai.com.br - January 4 at 11:53 PMVivos Inc Files a New Patent on Precision Radionuclide Therapy Support System Equipmentfinance.yahoo.com - January 3 at 2:06 PMReignite your passion with the vivo Y35philstar.com - October 12 at 8:10 PMVivo 6 GB RAM mobile phones: The ultimate buyer’s guidehindustantimes.com - October 10 at 5:47 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAethlon MedicalNASDAQ:AEMDAethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.Arch TherapeuticsOTCMKTS:ARTHArch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.InVivo TherapeuticsNASDAQ:NVIVInVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.VivosOTCMKTS:RDGLVivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States and internationally. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.